Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 53 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Pipeline Review, H1 2016', provides in depth analysis on Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) targeted pipeline therapeutics. 

The report provides comprehensive information on the Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27)
- The report reviews Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) Overview 7
Therapeutics Development 8
Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Products under Development by Stage of Development 8
Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Products under Development by Therapy Area 9
Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Products under Development by Indication 10
Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Products under Development by Companies 13
Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Products under Development by Universities/Institutes 15
Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Companies Involved in Therapeutics Development 24
Bayer AG 24
Bristol-Myers Squibb Company 25
Cambryn Biologics LLC 26
eXithera Pharmaceuticals, Inc 27
Ionis Pharmaceuticals, Inc. 28
LegoChem Biosciences, Inc 29
Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Drug Profiles 30
AB-022 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
BAY-1213790 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
BMS-262084 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
BMS-654457 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
coagulation factor XI (human) - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
coagulation factor XI (human) - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
IONIS-FXIRx - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Small Molecule 2 to Inhibit Factor XIa for Thrombosis - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Small Molecule to Inhibit Activated Factor XI for Bleeding Disorders - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Small Molecule to Inhibit Blood Factor XIa for CAHD and Stroke - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Small Molecules to Inhibit Factor XIa for Cardiovascular - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Small Molecules to Inhibit Factor XIa for Stroke and Thrombosis - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Dormant Projects 44
Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Featured News & Press Releases 45
Oct 30, 2015: Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis 45
Feb 24, 2015: Bayer HealthCare and Aronora Establish Partnership for the Pre-Clinical Manufacturing of AB-022 45
Dec 07, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery 46
Nov 18, 2014: Isis Pharmaceuticals To Host Webcast To Discuss ISIS-FXI Rx Data Presented At The ASH Annual Meeting 47
May 22, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx in the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery 47
Apr 19, 2013: CML HealthCare's Subsidiary Hemostasis Reference Labs Receives Contract Extension From Isis Pharma 48
Oct 29, 2012: Isis Pharma Initiates Phase II Study Of ISIS-FXIRX In Patients Undergoing Knee Replacement Surgery 49
Dec 12, 2011: Isis Reports Positive Phase I Data Demonstrating ISIS-FXIRx Reduces Factor XI Activity Without Bleeding 49
Feb 02, 2011: Isis Initiates Phase I Clinical Trial Of ISIS-FXIRx To Treat Clotting Disorders 51
Dec 03, 2009: Isis Pharmaceuticals Adds ISIS-FXIRx To Development Pipeline For The Treatment Of Clotting Disorders 51
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 52
Disclaimer 53

List of Tables

Number of Products under Development for, H1 2016 8
Number of Products under Development by Therapy Area, H1 2016 9
Number of Products under Development by Indication, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Products under Development by Companies, H1 2016 14
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Products under Investigation by Universities/Institutes, H1 2016 16
Assessment by Monotherapy/Combination Products, H1 2016 17
Number of Products by Stage and Mechanism of Action, H1 2016 19
Number of Products by Stage and Route of Administration, H1 2016 21
Number of Products by Stage and Molecule Type, H1 2016 23
Pipeline by Bayer AG, H1 2016 24
Pipeline by Bristol-Myers Squibb Company, H1 2016 25
Pipeline by Cambryn Biologics LLC, H1 2016 26
Pipeline by eXithera Pharmaceuticals, Inc, H1 2016 27
Pipeline by Ionis Pharmaceuticals, Inc., H1 2016 28
Pipeline by LegoChem Biosciences, Inc, H1 2016 29
Dormant Projects, H1 2016 44